title: [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].
abstract: Results from a phase II trial with Tesofensine for treatment of obesity are presented. In total 203 obese persons were randomised to treatment with Tesofensine 0.25, 0.5, or 1.0 mg, or placebo daily for 24 weeks. Treatment with Tesofensine resulted in a mean weight reduction of 4.5, 9.2 and 10.6% higher than that of placebo for 0.25, 0.5 and 1.0 mg, respectively. Tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved anti-obesity drugs. Findings of safety and efficacy of 0.5 mg Tesofensine need confirmation in phase III trials.
authors.affiliation: Institut for Human Ernaering, Det Biovidenskabelige Fakultet, Københavns Universitet, DK-1958 Frederiksberg C. alhn@life.ku.dk
authors.forename: Anne-Louise Hother
authors.initials: AL
authors.lastname: Nielsen
authors.forename: Thomas Meinert
authors.initials: TM
authors.lastname: Larsen
authors.forename: Sten
authors.initials: S
authors.lastname: Madsbad
authors.forename: Leif
authors.initials: L
authors.lastname: Breum
authors.forename: Thomas Jon
authors.initials: TJ
authors.lastname: Jensen
authors.forename: Jens Peter
authors.initials: JP
authors.lastname: Kroustrup
authors.forename: Arne
authors.initials: A
authors.lastname: Astrup
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects*; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D013997:Time Factors; D016896:Treatment Outcome; D015431:Weight Loss; D055815:Young Adult
chemical_list: D019440:Anti-Obesity Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; C518479:Tesofensine